SCHEMBL542239

SCHEMBL542239

CCN(CC)CCNC(=O)c1ccccc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.74
ALDH1A1 P00352 3/20 0.71
LMNA P02545 3/20 0.71
SLC22A2 O15244 1/20 0.71
SLC22A1 O15245 1/20 0.71
TSHR P16473 1/20 0.71
ACHE P22303 1/20 0.71
MAPK1 P28482 1/20 0.71
CYP2C19 P33261 1/20 0.71
BLM P54132 2/20 0.69
PMP22 Q01453 1/20 0.69
NFKB1 P19838 1/20 0.66
KCNH2 Q12809 1/20 0.66
POLB P06746 3/20 0.64
CYP3A4 P08684 1/20 0.64
THRB P10828 1/20 0.64
ATM Q13315 1/20 0.64
SMN1; SMN2 Q16637 1/20 0.64
MCHR1 Q99705 2/20 0.64
KDM4E B2RXH2 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7576777 0.98 TDP1 (0.72) TDP1ALDH1A1LMNASLC22A2SLC22A1
SCHEMBL28198442 0.91 ALDH1A1 (0.68) TDP1ALDH1A1LMNASLC22A2SLC22A1
SCHEMBL9628332 0.90 NAAA (0.64) TDP1ALDH1A1LMNASLC22A2SLC22A1
SCHEMBL1499569 0.90 TDP1 (0.92) TDP1ALDH1A1LMNASLC22A2SLC22A1
SCHEMBL10872900 0.89 LMNA (0.62) TDP1ALDH1A1LMNASLC22A2SLC22A1
SCHEMBL9254351 0.88 ALDH1A1 (0.74) TDP1ALDH1A1LMNASLC22A2SLC22A1
SCHEMBL16260997 0.87 TDP1 (0.60) TDP1ALDH1A1LMNASLC22A2SLC22A1
SCHEMBL10872544 0.87 TDP1 (0.60) TDP1ALDH1A1LMNASLC22A2SLC22A1
SCHEMBL10872304 0.87 TDP1 (0.60) TDP1ALDH1A1LMNASLC22A2SLC22A1
SCHEMBL12767062 0.86 MCHR1 (0.64) TDP1ALDH1A1LMNASLC22A2SLC22A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3836912-B1 COMBINATIONS OF SUBSTITUTED BENZAMIDES AND 5-ASA AGENTS PHARMACYL AB (SE) 2024-05-01 EP claimed
EP-1562640-B1 METHODS FOR PURIFYING RADIOLABELLED COMPOUNDS UNIV MCMASTER (CA) 2012-12-05 EP claimed
CN-101663267-A Subsituted sulphonamides, process for their preparation, pharmaceutical composition comprising thereof and their use UNIMED PHARMA SPOL SRO 2010-03-03 CN claimed
US-7335347-B2 Methods for purifying radiolabelled compounds MCMASTER UNIVERSITY (CA) 2008-02-26 US claimed
EP-1562640-A2 METHODS FOR PURIFYING RADIOLABELLED COMPOUNDS Molecular Insight Pharmaceuticals, Inc. (US) 2005-08-17 EP claimed
US-20040260073-A1 Methods for purifying radiolabelled compounds MCMASTER UNIVERSITY (CA) 2004-12-23 US claimed
WO-2004035744-A2 METHODS FOR PURIFYING RADIOLABELLED COMPOUNDS BIOSTREAM, INC. (US) 2004-04-29 WO claimed
EP-1127051-A2 TRICYCLIC PYRAZOLE DERIVATIVES BASF AKTIENGESELLSCHAFT (DE) 2001-08-29 EP claimed
WO-2000027822-A2 TRICYCLIC PYRAZOLE DERIVATIVES BASF AKTIENGESELLSCHAFT (DE) 2000-05-18 WO claimed
US-20260139240-A1 SUBTILASE CYTOTOXIN B SUBUNIT MUTANT GRIFFITH UNIVERSITY (AU) 2026-05-21 US disclosed
CN-122037555-A Flame-retardant high-resistivity bending-resistant polyamide composition and processing method thereof 山东大杼新材料有限公司 2026-05-15 CN disclosed
US-12480021-B2 Composition for semiconductor process, method for preparing the same and method for preparing semiconductor device using the same SK ENPULSE CO., LTD. (KR) 2025-11-25 US disclosed
EP-4622671-A1 NANOPARTICLE DISPERSIONS COMPRISING THERAPEUTIC AGENTS Morrison, Eric (US) 2025-10-01 EP disclosed
US-20250213473-A1 HIGHLY TRANSPARENT WATER CONTINUOUS DENSE NANOLIPID FLUID (DNLF) DISPERSIONS AND METHOD OF PREPARATION USING A TWIN SCREW EXTRUDER MORRISON Eric (US) 2025-07-03 US disclosed
US-4326067-A FROM OXAZOLINE WITH AN AMINE THE DOW CHEMICAL COMPANY (US) 1982-04-20 US disclosed
EP-0028331-A1 Process for preparing urethanes BAYER AG (DE) 1981-05-13 EP disclosed
EP-0027940-A1 Process for preparing urethanes BAYER AG (DE) 1981-05-06 EP disclosed
EP-0027952-A1 Process for preparing N,O-disubstituted urethanes BAYER AG (DE) 1981-05-06 EP disclosed
EP-0027953-A1 Process for preparing N,O-disubstituted urethanes BAYER AG (DE) 1981-05-06 EP disclosed
US-4006232-A Therapeutic method of treating cardiac arrhythmias utilizing 3-substituted diphenylhydantoins MILES LABORATORIES, INC. (US) 1977-02-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260139240-A1 SUBTILASE CYTOTOXIN B SUBUNIT MUTANT ENGASE, SPPL2B, NEU2 TDP1 1490/4885ALDH1A1 4316/4885LMNA 984/4885
US-20040260073-A1 Methods for purifying radiolabelled compounds PAICS, PFAS, NPEPPS TDP1 2547/4885ALDH1A1 2125/4885LMNA 3978/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.